Hamano, Takayuki http://orcid.org/0000-0002-2100-9106
Yamaguchi, Yusuke http://orcid.org/0000-0002-8589-5303
Goto, Kashia
Martin, Shaka
Jiletcovici, Alina
Dellanna, Frank
Akizawa, Tadao http://orcid.org/0000-0002-6150-9201
Barratt, Jonathan http://orcid.org/0000-0002-9063-7229
Clinical trials referenced in this document:
Documents that mention this clinical trial
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
https://doi.org/10.1007/s12325-023-02728-2
Documents that mention this clinical trial
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD
https://doi.org/10.34067/kid.0001442022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
https://doi.org/10.1681/asn.2020111638
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
https://doi.org/10.1053/j.ajkd.2015.12.020
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
https://doi.org/10.1007/s12325-023-02728-2
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
https://doi.org/10.1007/s12325-023-02433-0
Documents that mention this clinical trial
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD
https://doi.org/10.34067/kid.0001442022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
https://doi.org/10.1681/asn.2020111638
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
https://doi.org/10.1007/s12325-023-02728-2
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
https://doi.org/10.1007/s12325-023-02433-0
Documents that mention this clinical trial
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD
https://doi.org/10.34067/kid.0001442022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
https://doi.org/10.1681/asn.2020111638
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
https://doi.org/10.1007/s12325-023-02728-2
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
https://doi.org/10.1007/s12325-023-02433-0
Funding for this research was provided by:
Astellas Pharma, Inc.
Article History
Received: 11 July 2023
Accepted: 1 November 2023
First Online: 16 February 2024
Declarations
:
: Takayuki Hamano has received grants for physician-initiated research, consulting fees and honoraria for lectures from Astellas Pharma, Inc. Yusuke Yamaguchi is an employee of Astellas Pharma, Inc. Kashia Goto has participated in a company stock ownership plan through Astellas Pharma, Inc. Shaka Martin is an employee of Astellas Pharma, Inc. Alina Jiletcovici has received stock or stock options as a minor shareholder for Eli Lilly and Company and is an employee of Astellas Pharma, Inc. Frank Dellanna has nothing to disclose. Tadao Akizawa has received personal consulting fees from Astellas Pharma, Inc., Kyowa Kirin, Kissei Pharmaceutical, Ono Pharmaceutical, Fuso Pharmaceutical, Torii Pharmaceutical, GlaxoSmithKline, JT Pharmaceutical, Nipro Corporation, Otsuka, Sanwa Kagaku and Bayer and has also received personal payment or honoraria for lectures from Astellas Pharma, Inc., Kyowa Kirin, Kissei Pharmaceutical, Ono Pharmaceutical, Fuso Pharmaceutical I, Torii Pharmaceutical, Chugai Pharmaceutical, Mitsubishi Tanabe, and Bayer. Jonathan Barratt has received fees for invited lectures from Astellas Pharma, Inc.
: All studies included in this post hoc analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki of 1964 and its later amendments, the International Conference on Harmonisation of Technical Requirements for Pharmaceutical for Human Use guidelines, Good Clinical Practice, and applicable local laws and regulations. As this was a pooled post hoc analysis, approval by an ethics committee for this analysis was not necessary; however, institutional review board approval was obtained prior to initiating each of the included studies. All participants provided written informed consent.